全文获取类型
收费全文 | 3078篇 |
免费 | 259篇 |
国内免费 | 3篇 |
出版年
2023年 | 12篇 |
2022年 | 20篇 |
2021年 | 56篇 |
2020年 | 33篇 |
2019年 | 36篇 |
2018年 | 39篇 |
2017年 | 37篇 |
2016年 | 77篇 |
2015年 | 115篇 |
2014年 | 127篇 |
2013年 | 168篇 |
2012年 | 266篇 |
2011年 | 222篇 |
2010年 | 148篇 |
2009年 | 140篇 |
2008年 | 197篇 |
2007年 | 192篇 |
2006年 | 204篇 |
2005年 | 162篇 |
2004年 | 203篇 |
2003年 | 153篇 |
2002年 | 155篇 |
2001年 | 55篇 |
2000年 | 27篇 |
1999年 | 38篇 |
1998年 | 38篇 |
1997年 | 29篇 |
1996年 | 17篇 |
1995年 | 26篇 |
1994年 | 20篇 |
1993年 | 31篇 |
1992年 | 23篇 |
1991年 | 17篇 |
1990年 | 23篇 |
1989年 | 23篇 |
1988年 | 16篇 |
1987年 | 12篇 |
1986年 | 20篇 |
1985年 | 21篇 |
1984年 | 10篇 |
1983年 | 14篇 |
1982年 | 16篇 |
1981年 | 10篇 |
1980年 | 7篇 |
1979年 | 8篇 |
1978年 | 7篇 |
1976年 | 7篇 |
1974年 | 8篇 |
1972年 | 7篇 |
1970年 | 5篇 |
排序方式: 共有3340条查询结果,搜索用时 15 毫秒
991.
992.
Jeff Butler Kathryn A. Hooper Stephen Petrie Raphael Lee Sebastian Maurer-Stroh Lucia Reh Teagan Guarnaccia Chantal Baas Lumin Xue Sophie Vitesnik Sook-Kwan Leang Jodie McVernon Anne Kelso Ian G. Barr James M. McCaw Jesse D. Bloom Aeron C. Hurt 《PLoS pathogens》2014,10(4)
Oseltamivir is relied upon worldwide as the drug of choice for the treatment of human influenza infection. Surveillance for oseltamivir resistance is routinely performed to ensure the ongoing efficacy of oseltamivir against circulating viruses. Since the emergence of the pandemic 2009 A(H1N1) influenza virus (A(H1N1)pdm09), the proportion of A(H1N1)pdm09 viruses that are oseltamivir resistant (OR) has generally been low. However, a cluster of OR A(H1N1)pdm09 viruses, encoding the neuraminidase (NA) H275Y oseltamivir resistance mutation, was detected in Australia in 2011 amongst community patients that had not been treated with oseltamivir. Here we combine a competitive mixtures ferret model of influenza infection with a mathematical model to assess the fitness, both within and between hosts, of recent OR A(H1N1)pdm09 viruses. In conjunction with data from in vitro analyses of NA expression and activity we demonstrate that contemporary A(H1N1)pdm09 viruses are now more capable of acquiring H275Y without compromising their fitness, than earlier A(H1N1)pdm09 viruses circulating in 2009. Furthermore, using reverse engineered viruses we demonstrate that a pair of permissive secondary NA mutations, V241I and N369K, confers robust fitness on recent H275Y A(H1N1)pdm09 viruses, which correlated with enhanced surface expression and enzymatic activity of the A(H1N1)pdm09 NA protein. These permissive mutations first emerged in 2010 and are now present in almost all circulating A(H1N1)pdm09 viruses. Our findings suggest that recent A(H1N1)pdm09 viruses are now more permissive to the acquisition of H275Y than earlier A(H1N1)pdm09 viruses, increasing the risk that OR A(H1N1)pdm09 will emerge and spread worldwide. 相似文献
993.
994.
995.
Derek M. Erion Amanda Lapworth Paul A. Amor Guoyun Bai Nicholas B. Vera Ronald W. Clark Qingyun Yan Yimin Zhu Trenton T. Ross Julie Purkal Matthew Gorgoglione Guodong Zhang Vinicius Bonato Levenia Baker Nicole Barucci Theresa D’Aquila Alan Robertson Robert J. Aiello Jiangli Yan Jeff Trimmer Timothy P. Rolph Jeffrey A. Pfefferkorn 《PloS one》2014,9(5)
Hyperglycemia resulting from type 2 diabetes mellitus (T2DM) is the main cause of diabetic complications such as retinopathy and neuropathy. A reduction in hyperglycemia has been shown to prevent these associated complications supporting the importance of glucose control. Glucokinase converts glucose to glucose-6-phosphate and determines glucose flux into the β-cells and hepatocytes. Since activation of glucokinase in β-cells is associated with increased risk of hypoglycemia, we hypothesized that selectively activating hepatic glucokinase would reduce fasting and postprandial glucose with minimal risk of hypoglycemia. Previous studies have shown that hepatic glucokinase overexpression is able to restore glucose homeostasis in diabetic models; however, these overexpression experiments have also revealed that excessive increases in hepatic glucokinase activity may also cause hepatosteatosis. Herein we sought to evaluate whether liver specific pharmacological activation of hepatic glucokinase is an effective strategy to reduce hyperglycemia without causing adverse hepatic lipids changes. To test this hypothesis, we evaluated a hepatoselective glucokinase activator, PF-04991532, in Goto-Kakizaki rats. In these studies, PF-04991532 reduced plasma glucose concentrations independent of changes in insulin concentrations in a dose-dependent manner both acutely and after 28 days of sub-chronic treatment. During a hyperglycemic clamp in Goto-Kakizaki rats, the glucose infusion rate was increased approximately 5-fold with PF-04991532. This increase in glucose infusion can be partially attributed to the 60% reduction in endogenous glucose production. While PF-04991532 induced dose-dependent increases in plasma triglyceride concentrations it had no effect on hepatic triglyceride concentrations in Goto-Kakizaki rats. Interestingly, PF-04991532 decreased intracellular AMP concentrations and increased hepatic futile cycling. These data suggest that hepatoselective glucokinase activation may offer glycemic control without inducing hepatic steatosis supporting the evaluation of tissue specific activators in clinical trials. 相似文献
996.
Jeff W. Hill Jeffrey F. Thompson Mark B. Carter Bruce S. Edwards Larry A. Sklar Gary A. Rosenberg 《PloS one》2014,9(5)
Stroke is a leading cause of death and disability and treatment options are limited. A promising approach to accelerate the development of new therapeutics is the use of high-throughput screening of chemical libraries. Using a cell-based high-throughput oxygen-glucose deprivation (OGD) model, we evaluated 1,200 small molecules for repurposed application in stroke therapy. Isoxsuprine hydrochloride was identified as a potent neuroprotective compound in primary neurons exposed to OGD. Isoxsuprine, a β2-adrenergic agonist and NR2B subtype-selective N-methyl-D-aspartate (NMDA) receptor antagonist, demonstrated no loss of efficacy when administered up to an hour after reoxygenation in an in vitro stroke model. In an animal model of transient focal ischemia, isoxsuprine significantly reduced infarct volume compared to vehicle (137±18 mm3 versus 279±25 mm3, p<0.001). Isoxsuprine, a peripheral vasodilator, was FDA approved for the treatment of cerebrovascular insufficiency and peripheral vascular disease. Our demonstration of the significant and novel neuroprotective action of isoxsuprine hydrochloride in an in vivo stroke model and its history of human use suggest that isoxsuprine may be an ideal candidate for further investigation as a potential stroke therapeutic. 相似文献
997.
Aaron D. Besterman Thorsten Althoff Peter Elfferich Irma Gutierrez-Mejia Joshua Sadik Jonathan A. Bernstein Yvette van Ierland Anja A. Kattentidt-Mouravieva Mark Nellist Jeff Abramson Julian A. Martinez-Agosto 《PLoS genetics》2021,17(7)
Smith-Kingsmore syndrome (SKS) is a rare neurodevelopmental disorder characterized by macrocephaly/megalencephaly, developmental delay, intellectual disability, hypotonia, and seizures. It is caused by dominant missense mutations in MTOR. The pathogenicity of novel variants in MTOR in patients with neurodevelopmental disorders can be difficult to determine and the mechanism by which variants cause disease remains poorly understood. We report 7 patients with SKS with 4 novel MTOR variants and describe their phenotypes. We perform in vitro functional analyses to confirm MTOR activation and interrogate disease mechanisms. We complete structural analyses to understand the 3D properties of pathogenic variants. We examine the accuracy of relative accessible surface area, a quantitative measure of amino acid side-chain accessibility, as a predictor of MTOR variant pathogenicity.We describe novel clinical features of patients with SKS. We confirm MTOR Complex 1 activation and identify MTOR Complex 2 activation as a new potential mechanism of disease in SKS. We find that pathogenic MTOR variants disproportionately cluster in hotspots in the core of the protein, where they disrupt alpha helix packing due to the insertion of bulky amino acid side chains. We find that relative accessible surface area is significantly lower for SKS-associated variants compared to benign variants. We expand the phenotype of SKS and demonstrate that additional pathways of activation may contribute to disease. Incorporating 3D properties of MTOR variants may help in pathogenicity classification. We hope these findings may contribute to improving the precision of care and therapeutic development for individuals with SKS. 相似文献
998.
John B. Meixner Elena Labkovsky J. Peter Rosenfeld Michael Winograd Alexander Sokolovsky Jeff Weishaar Tim Ullmann 《Applied psychophysiology and biofeedback》2013,38(2):121-132
Countermeasures pose a serious threat to the effectiveness of the Concealed Information Test (CIT). In a CIT experiment, Rosenfeld and Labkovsky in Psychophysiology 47(6):1002–1010, (2010) observed a previously unknown positive ERP component at about 900 ms post-stimulus at Fz and Cz that could potentially serve as an index of countermeasure use. Here, we explored the hypothesis that this component, termed P900, occurs in response to a signal that no further specific response is required in a trial, and could thus appear in countermeasure users that respond differentially depending on the stimulus that appears. In the present experiments, subjects viewed four non-meaningful (irrelevant) dates and one oddball date. In three experiments, we examined P900’s antecedent conditions. In the first, the unique item was a personally relevant oddball (the subject’s birthdate). In a second, the unique item was a non-personally relevant oddball (an irrelevant date in a unique font color). In a third, all dates were irrelevant. We speculated that the presence of an oddball would not be necessary for P900. All participants made countermeasure-like responses following two specific irrelevant dates. As hypothesized, P900s were seen to non-responded-to irrelevant and oddball stimuli in all subjects but not to responded-to irrelevant stimuli, and the presence of an oddball was not necessary for elicitation of P900. This finding has potential application in deception settings—the presence of a P300 accompanied by the presence of a P900 in response to non-countered stimuli could provide evidence of incriminating knowledge accompanied by the attempt to use countermeasures to evade detection. 相似文献
999.
Srikanth Nagalla Jeff W Chou Mark C Willingham Jimmy Ruiz James P Vaughn Purnima Dubey Timothy L Lash Stephen J Hamilton-Dutoit Jonas Bergh Christos Sotiriou Michael A Black Lance D Miller 《Genome biology》2013,14(4):R34
Background
Gene expression signatures indicative of tumor proliferative capacity and tumor-immune cell interactions have emerged as principal biology-driven predictors of breast cancer outcomes. How these signatures relate to one another in biological and prognostic contexts remains to be clarified.Results
To investigate the relationship between proliferation and immune gene signatures, we analyzed an integrated dataset of 1,954 clinically annotated breast tumor expression profiles randomized into training and test sets to allow two-way discovery and validation of gene-survival associations. Hierarchical clustering revealed a large cluster of distant metastasis-free survival-associated genes with known immunological functions that further partitioned into three distinct immune metagenes likely reflecting B cells and/or plasma cells; T cells and natural killer cells; and monocytes and/or dendritic cells. A proliferation metagene allowed stratification of cases into proliferation tertiles. The prognostic strength of these metagenes was largely restricted to tumors within the highest proliferation tertile, though intrinsic subtype-specific differences were observed in the intermediate and low proliferation tertiles. In highly proliferative tumors, high tertile immune metagene expression equated with markedly reduced risk of metastasis whereas tumors with low tertile expression of any one of the three immune metagenes were associated with poor outcome despite higher expression of the other two metagenes.Conclusions
These findings suggest that a productive interplay among multiple immune cell types at the tumor site promotes long-term anti-metastatic immunity in a proliferation-dependent manner. The emergence of a subset of effective immune responders among highly proliferative tumors has novel prognostic ramifications. 相似文献1000.
Laura E. Walls Koray Malc Behnaz Nowrouzi Rachel A. Li Leo d'Espaux Jeff Wong Jonathan A. Dennis Andrea J. C. Semio Stephen Wallace Jos L. Martinez Jay D. Keasling Leonardo Rios‐Solis 《Biotechnology and bioengineering》2021,118(1):279-293
Taxadien‐5α‐hydroxylase and taxadien‐5α‐ol O‐acetyltransferase catalyze the oxidation of taxadiene to taxadien‐5α‐ol and subsequent acetylation to taxadien‐5α‐yl‐acetate in the biosynthesis of the blockbuster anticancer drug, paclitaxel (Taxol®). Despite decades of research, the promiscuous and multispecific CYP725A4 enzyme remains a major bottleneck in microbial biosynthetic pathway development. In this study, an interdisciplinary approach was applied for the construction and optimization of the early pathway in Saccharomyces cerevisiae, across a range of bioreactor scales. High‐throughput microscale optimization enhanced total oxygenated taxane titer to 39.0 ± 5.7 mg/L and total taxane product titers were comparable at micro and minibioreactor scale at 95.4 ± 18.0 and 98.9 mg/L, respectively. The introduction of pH control successfully mitigated a reduction of oxygenated taxane production, enhancing the potential taxadien‐5α‐ol isomer titer to 19.2 mg/L, comparable with the 23.8 ± 3.7 mg/L achieved at microscale. A combination of bioprocess optimization and increased gas chromatography‐mass spectrometry resolution at 1 L bioreactor scale facilitated taxadien‐5α‐yl‐acetate detection with a final titer of 3.7 mg/L. Total oxygenated taxane titers were improved 2.7‐fold at this scale to 78 mg/L, the highest reported titer in yeast. Critical parameters affecting the productivity of the engineered strain were identified across a range of scales, providing a foundation for the development of robust integrated bioprocess control systems. 相似文献